Literature DB >> 34845561

Quantitative assessment of the effect of FGF20 rs1721100 and rs12720208 variant on the risk of sporadic Parkinson's disease: a meta-analysis.

Wei Quan1, Jia Li1, Li Liu1, Qinghui Zhang1, Yidan Qin1, Xiaochen Pei1, Jiajun Chen2.   

Abstract

OBJECTIVES: While many studies have investigated the associations between fibroblast growth factor 20 (FGF20) rs1721100 (C/G) and rs12720208 (C/T) polymorphisms and susceptibility to Parkinson's disease (PD), their results are controversial. Our present meta-analysis estimated the overall association between FGF20 rs1721100 and rs12720208 polymorphisms and the risk of sporadic PD.
METHODS: We performed a comprehensive literature search of the PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang Medicine electronic databases, which was updated in April 2021. Based on strict inclusion and exclusion criteria, the analysis included a total of 10 papers involving 14 studies with 5262 cases of PD and 6075 controls. Review Manager 5.4 software was used to assess the available data from each study. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between the FGF20 rs1721100 and rs12720208 polymorphisms and sporadic PD risk.
RESULTS: Our results showed that the FGF20 rs1721100 G allele frequency and genotype distribution did not differ between PD patients and controls. Similarly, the FGF20 rs12720208 T allele frequency and genotype distribution did not differ significantly between the two groups. A subgroup analysis of Asian and Caucasian populations also showed the same results.
CONCLUSIONS: The results of this meta-analysis indicated that neither the rs1721100 C/G nor the rs12720208 C/T variants were associated with sporadic PD susceptibility.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  FGF20; Gene polymorphism; Meta-analysis; Parkinson’s disease; rs12720208; rs1721100

Mesh:

Substances:

Year:  2021        PMID: 34845561     DOI: 10.1007/s10072-021-05754-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  33 in total

1.  Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c.

Authors:  Shigeki Ohmachi; Tadahisa Mikami; Morichika Konishi; Ayumi Miyake; Nobuyuki Itoh
Journal:  J Neurosci Res       Date:  2003-05-15       Impact factor: 4.164

2.  Parkinson's Disease: A Review from Pathophysiology to Treatment.

Authors:  Bianca L B Marino; Lucilene R de Souza; Kessia P A Sousa; Jaderson V Ferreira; Elias C Padilha; Carlos H T P da Silva; Carlton A Taft; Lorane I S Hage-Melim
Journal:  Mini Rev Med Chem       Date:  2020       Impact factor: 3.862

3.  Molecular cloning and characterization of human FGF-20 on chromosome 8p21.3-p22.

Authors:  H Kirikoshi; N Sagara; T Saitoh; K Tanaka; H Sekihara; K Shiokawa; M Katoh
Journal:  Biochem Biophys Res Commun       Date:  2000-08-02       Impact factor: 3.575

4.  FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain.

Authors:  S Ohmachi; Y Watanabe; T Mikami; N Kusu; T Ibi; A Akaike; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

Review 5.  Genetics and genomics of Parkinson's disease.

Authors:  Michelle K Lin; Matthew J Farrer
Journal:  Genome Med       Date:  2014-06-30       Impact factor: 11.117

6.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Authors:  Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton
Journal:  Nat Genet       Date:  2014-07-27       Impact factor: 38.330

7.  Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats.

Authors:  Edward J R Fletcher; Aran D Jamieson; Gareth Williams; Patrick Doherty; Susan Duty
Journal:  Sci Rep       Date:  2019-06-06       Impact factor: 4.379

8.  Roles of FGF20 in dopaminergic neurons and Parkinson's disease.

Authors:  Nobuyuki Itoh; Hiroya Ohta
Journal:  Front Mol Neurosci       Date:  2013-05-31       Impact factor: 5.639

9.  Cognitive or Cognitive-Motor Executive Function Tasks? Evaluating Verbal Fluency Measures in People with Parkinson's Disease.

Authors:  Alessandra Ferreira Barbosa; Mariana Callil Voos; Janini Chen; Debora Cristina Valente Francato; Carolina de Oliveira Souza; Egberto Reis Barbosa; Hsin Fen Chien; Letícia Lessa Mansur
Journal:  Biomed Res Int       Date:  2017-08-20       Impact factor: 3.411

10.  Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.

Authors:  Eugene L Boshoff; Edward J R Fletcher; Susan Duty
Journal:  Neuropharmacology       Date:  2018-04-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.